Clinical TrialsManagement reports interest from multiple parties in its Phase 3 dry eye disease program and early-stage programs, indicating potential out-licensing opportunities.
Inflammatory DiseasesPL9643 showed a rapid onset of efficacy, with multiple symptom endpoints achieving statistical significance at the 2-week mark and continuing to improve throughout the 12-week treatment period, setting the stage for two additional Phase 3 trials.
Obesity TreatmentPalatin's novel MC4R-selective agonists have potential both as monotherapy and in combination therapy to address obesity, expanding treatment options.